November 21, 2016 - By Peter Erickson · 0 Comments
Transgenomic Inc (NASDAQ:TBIO) institutional sentiment increased to 1.8 in 2016 Q2. Its up 1.17, from 0.63 in 2016Q1. The ratio has improved, as 5 institutional investors opened new or increased equity positions, while 8 cut down and sold stakes in Transgenomic Inc. The institutional investors in our partner’s database now possess: 8.44 million shares, down from 8.48 million shares in 2016Q1. Also, the number of institutional investors holding Transgenomic Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 4 Increased: 3 New Position: 2.
Transgenomic, Inc. is a biotechnology company. The company has a market cap of $4.39 million. The Firm is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. It currently has negative earnings. The Firm operates through its Laboratory Services segment.
About 826 shares traded hands. Transgenomic Inc (NASDAQ:TBIO) has declined 76.39% since April 19, 2016 and is downtrending. It has underperformed by 80.25% the S&P500.
According to Zacks Investment Research, “Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variations in the human genetic code. The company believes its WAVE System, which incorporates its proprietary DNASep separation column and associated software, chemical reagents and other consumable items, will become a leading tool to analyze genetic mutations. The WAVE System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other techniques.”
Third Security Llc holds 0.22% of its portfolio in Transgenomic Inc for 7.55 million shares. White Pine Capital Llc owns 218,579 shares or 0.05% of their US portfolio. Moreover, Advisory Services Network Llc has 0% invested in the company for 1,974 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 2,797 shares.#img1#
Transgenomic, Inc. (Transgenomic), incorporated on March 6, 1997, is a biotechnology company. The Firm is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Firm operates through its Laboratory Services segment. The Firm is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR).
More recent Transgenomic Inc (NASDAQ:TBIO) news were published by: Businesswire.com which released: “Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of …” on July 14, 2015. Also Businesswire.com published the news titled: “Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and …” on January 19, 2016. Businesswire.com‘s news article titled: “Transgenomic Acquires ScoliScoreâ„¢ Adolescent Idiopathic Scoliosis Prognostic …” with publication date: August 28, 2012 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson